name
stringlengths 8
13
| light_chain_class
stringclasses 2
values | type
stringclasses 5
values | original_mab_isotype_or_format
stringclasses 17
values | clinical_status
stringclasses 3
values | phagec
bool 2
classes | year_name_proposed
int64 1.99k
2.01k
| metadata_notes
stringclasses 3
values | vh
stringlengths 112
130
| vl
stringlengths 104
113
| lc_class
stringclasses 2
values | source
stringclasses 3
values | source_detaileda
stringlengths 4
9
| disclaimers_and_known_issues
stringclasses 6
values | sequence_info_notes
stringclasses 1
value | hek_titer_mg_l
float64 6.58
277
| fab_tm_by_dsf_deg_c
float64 59.5
91.5
| sgac_sins_as100_nh4_2so4_mm
float64 0
1k
| hic_retention_time_min_a
float64 8.47
25
| smac_retention_time_min_a
float64 8.49
25
| slope_for_accelerated_stability
float64 -0.01
1.27
| poly_specificity_reagent_psr_smp_score_0_1
float64 0
0.81
| affinity_capture_self_interaction_nanoparticle_spectroscopy_ac_sins_delta_lambda_max_nm_average
float64 -1.08
29.9
| cic_retention_time_min
float64 8.26
13.5
| csi_bli_delta_response_nm
float64 -0.05
0.6
| elisa
float64 0.89
14.5
| bvp_elisa
float64 1.03
22.7
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
pembrolizumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Approved
| false
| 2,013
| null |
QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
RL72
| null | null | 64.908983
| 66
| 500
| 11.073
| 13.477
| 0.0334
| 0.300425
| 5.622347
| 10.918
| 0.01
| 1.277062
| 2.234276
|
pertuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,003
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK
|
kappa
|
PDB
|
1S78
| null | null | 31.426915
| 78.5
| 700
| 10.112
| 8.913
| 0.03917
| 0
| -0.203825
| 8.597
| -0.04
| 1.213583
| 1.691847
|
pinatuzumab
|
kappa
|
ZU
|
IgG1-ADC
|
Phase 2
| false
| 2,012
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL108
| null | null | 130.580857
| 79
| 800
| 9.224
| 8.827
| 0.06846
| 0.011366
| 0.589521
| 8.774
| -0.02
| 1.272171
| 2.485191
|
polatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true
| 2,012
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS
|
DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL108
| null | null | 225.055164
| 74
| 1,000
| 8.763
| 8.67
| 0.05931
| 0
| -1.003168
| 8.264
| -0.05
| 1.362537
| 3.622629
|
ponezumab
|
kappa
|
ZU
|
IgG2
|
Phase 2
| true
| 2,010
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS
|
DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 16.95786
| 61
| 800
| 10.499
| 9.004
| 0.1568
| 0.074359
| -0.239908
| 8.679
| -0.03
| 3.130063
| 6.623627
|
radretumab
|
kappa
|
HU
|
scFv-CH
|
Phase 2
| true
| 2,010
| null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 151.171797
| 77
| 900
| 9.514
| 8.69
| 0.001743
| 0.133677
| 3.384699
| 8.858
| 0
| 1.259504
| 3.286522
|
ramucirumab
|
kappa
|
HU
|
IgG1
|
Approved
| true
| 2,008
| null |
EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS
|
DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 90.668096
| 66
| 900
| 9.43
| 8.705
| 0.02434
| 0
| 0.015844
| 8.582
| -0.02
| 1.054893
| 1.249917
|
ranibizumab
|
kappa
|
ZU
|
Fab
|
Approved
| true
| 2,004
| null |
EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS
|
DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
|
kappa
|
PDB
|
1CZ8
| null | null | 41.447866
| 65
| 300
| 12.142
| 18.059
| 0.0942
| 0
| 7.925273
| 10.058
| 0.02
| 1.607124
| 3.138103
|
reslizumab
|
kappa
|
ZU
|
IgG4
|
Approved
| false
| 2,001
| null |
EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK
|
kappa
|
US Patent
|
US5998586
| null | null | 191.568526
| 75.5
| 700
| 9.824
| 8.9
| 0.06217
| 0.23029
| 1.739301
| 8.864
| 0
| 1.251463
| 2.023295
|
rilotumumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false
| 2,009
| null |
QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS
|
EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 173.077795
| 79
| 500
| 12.633
| 17.684
| 1.2728
| 0.160022
| 2.12658
| 10.393
| 0
| 1.130871
| 2.373034
|
rituximab
|
kappa
|
XI
|
IgG1
|
Approved
| false
| 1,997
| null |
QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA
|
QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK
|
kappa
|
PDB
|
2OSL
| null | null | 164.141012
| 69
| 700
| 10.797
| 9.109
| 0.025
| 0.383866
| 2.133138
| 10.147
| -0.01
| 1.190297
| 2.929118
|
robatumumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false
| 2,008
| null |
EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS
|
EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 117.115691
| 80
| 0
| 9.507
| 8.969
| 0.04534
| 0.266657
| 29.645095
| 9.752
| 0.14
| 5.219351
| 8.246256
|
romosozumab
|
kappa
|
ZU
|
IgG2
|
Phase 3
| false
| 2,011
| null |
EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL106
| null | null | 227.687243
| 76
| 1,000
| 9.18
| 8.648
| 0.02831
| 0
| -1.019466
| 8.427
| -0.03
| 1.007345
| 1.46822
|
sarilumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| false
| 2,011
| null |
EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS
|
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL106
| null | null | 181.786077
| 64
| 900
| 8.989
| 8.687
| 0.04986
| 0
| 1.113824
| 8.71
| -0.01
| 1.186912
| 2.168386
|
secukinumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,009
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK
|
kappa
|
WHO-INN
|
PL102
| null | null | 148.958796
| 72
| 800
| 11.389
| 8.906
| 0.0492
| 0
| -0.584713
| 8.361
| -0.04
| 1.088862
| 1.694757
|
seribantumab
|
lambda
|
HU
|
IgG2
|
Phase 2
| true
| 2,012
| null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS
|
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL
|
lambda
|
WHO-INN
|
PL108
| null | null | 189.98314
| 77.5
| 300
| 10.418
| 8.998
| 0.1544
| 0
| 21.208264
| 9.787
| 0.01
| 1.237431
| 2.97371
|
sifalimumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false
| 2,009
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 158.632742
| 67
| 800
| 9.651
| 8.773
| 0.01314
| 0.06062
| 2.100484
| 9.02
| -0.02
| 2.595419
| 2.497171
|
siltuximab
|
kappa
|
XI
|
IgG1
|
Approved
| false
| 2,008
| null |
EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS
|
QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 95.667173
| 64.5
| 600
| 10.999
| 12.076
| 0.0133
| 0
| 2.637658
| 9.42
| -0.01
| 1.175326
| 1.549813
|
simtuzumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 2
| false
| 2,012
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS
|
DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 191.435366
| 66.5
| 800
| 10.407
| 9.571
| 0.1421
| 0.336875
| 0.880686
| 9.098
| 0
| 6.008056
| 10.411314
|
sirukumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| true
| 2,011
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS
|
EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 109.806712
| 68
| 0
| 11.26
| 10.756
| 0.03969
| 0.359874
| 29.645095
| 10.79
| 0.08
| 2.174539
| 9.657903
|
tabalumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 3
| false
| 2,011
| null |
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 121.595499
| 64
| 700
| 10.847
| 9.87
| 0.0618
| 0
| 1.955361
| 9.127
| -0.01
| 1.260386
| 3.681864
|
tanezumab
|
kappa
|
ZU
|
IgG2
|
Phase 3
| true
| 2,008
| null |
QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK
|
kappa
|
PDB
|
4EDW
| null | null | 48.863766
| 75.5
| 700
| 12.386
| 10.689
| 0.0166
| 0.229612
| 2.171174
| 9.248
| -0.01
| 1.396358
| 4.827715
|
teplizumab
|
kappa
|
ZU
|
IgG1AA-mut
|
Phase 3
| false
| 2,007
| null |
QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT
|
kappa
|
WHO-INN
|
PL97
| null | null | 150.875165
| 64.5
| 1,000
| 8.786
| 8.647
| 0.06126
| 0.311282
| 11.167121
| 9.365
| 0.02
| 1.673976
| 3.844925
|
tigatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,007
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL98
| null | null | 178.9678
| 64.5
| 700
| 10.02
| 8.732
| 0.0029
| 0.12877
| 5.489286
| 8.7
| -0.01
| 1.172939
| 1.702622
|
tildrakizumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false
| 2,012
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL108
| null | null | 181.888073
| 77.5
| 600
| 11.079
| 9.868
| -0.005
| 0
| 0.814903
| 8.728
| -0.01
| 1.186253
| 1.769052
|
tocilizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 2,004
| null |
QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK
|
kappa
|
US Patent
|
US5795965
| null | null | 139.649467
| 91.5
| 900
| 9.088
| 8.777
| 0.04516
| 0
| 1.318283
| 8.902
| 0
| 1.13555
| 2.807987
|
tovetumab
|
kappa
|
HU
|
IgG2
|
Phase 2
| false
| 2,013
| null |
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK
|
kappa
|
WHO-INN
|
PL109
| null | null | 277.180752
| 63.5
| 900
| 8.673
| 8.634
| 0.0131
| 0
| 2.245154
| 8.808
| -0.01
| 1.352145
| 2.951685
|
tralokinumab
|
lambda
|
HU
|
IgG4
|
Phase 3
| true
| 2,009
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS
|
SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL102
| null | null | 121.427053
| 63
| 800
| 10.262
| 8.987
| 0.007743
| 0.157394
| 4.813687
| 8.8
| 0.09
| 1.286288
| 2.315474
|
trastuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false
| 1,997
| null |
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL103_ADC
|
Sequences taken from trastuzumab emtansine; identical to trastuzumab from other sources
| null | 159.477627
| 78.5
| 800
| 9.657
| 8.752
| 0.04383
| 0
| 2.038127
| 8.843
| -0.02
| 1.063455
| 1.336439
|
tremelimumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false
| 2,005
| null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK
|
kappa
|
US Patent
|
US6682736
| null | null | 229.592511
| 75
| 0
| 11.557
| 19.316
| 0.01757
| 0.145497
| 29.645095
| 11.242
| 0
| 1.211239
| 1.965391
|
urelumab
|
kappa
|
HU
|
IgG4
|
Phase 2
| false
| 2,010
| null |
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL104
|
VL sequence modified at one position to match patent document (US7659384) and JK germline
| null | 143.923958
| 66
| 0
| 11.161
| 12.985
| 0.01389
| 0
| 29.645095
| 9.369
| 0.07
| 1.146375
| 1.531448
|
ustekinumab
|
kappa
|
HU
|
IgG1
|
Approved
| false
| 2,008
| null |
EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK
|
kappa
|
PDB
|
3HMW
| null | null | 152.722928
| 69.5
| 1,000
| 8.783
| 8.64
| 0.02254
| 0.153653
| 0.424236
| 8.633
| -0.01
| 2.184532
| 5.07421
|
vedolizumab
|
kappa
|
ZU
|
IgG1AA-mut
|
Approved
| false
| 2,008
| null |
QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS
|
DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 221.762037
| 80.5
| 600
| 10.942
| 12.307
| 0.06906
| 0
| 0.388178
| 8.986
| -0.02
| 1.152671
| 1.584027
|
veltuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false
| 2,007
| null |
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS
|
DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL98
| null | null | 224.953517
| 70
| 700
| 11.092
| 9.725
| 0.0399
| 0
| 4.831871
| 8.792
| -0.02
| 0.888809
| 1.211236
|
visilizumab
|
kappa
|
ZU
|
IgG2
|
Phase 3
| false
| 2,000
| null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK
|
kappa
|
US Patent
|
US7381803
| null | null | 242.006377
| 71
| 0
| 9.007
| 8.695
| 0.0576
| 0.418071
| 21.988193
| 9.146
| 0.01
| 1.880772
| 4.799334
|
zalutumumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| false
| 2,005
| null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS
|
AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
|
kappa
|
US Patent
|
US8586041
| null | null | 200.50669
| 72.5
| 900
| 9.335
| 8.738
| 0.04983
| 0
| -0.79679
| 8.415
| -0.03
| 1.284363
| 2.896506
|
zanolimumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| false
| 2,004
| null |
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS
|
DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK
|
kappa
|
US Patent
|
US7722873
| null | null | 116.367688
| 80.5
| 700
| 9.586
| 8.768
| 0.02569
| 0.127128
| 1.457937
| 8.61
| -0.01
| 1.102262
| 1.455574
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.